We aimed to evaluate the accuracy of the dosage of calprotectin in ascitic fluid (AF) using the Quantum Blue assay, for the prompt diagnosis of spontaneous bacterial peritonitis (SBP).
INTRODUCTION

B
ACTERIAL INFECTIONS DRAMATICALLY increase the probability of death in patients with decompensated cirrhosis by up to 3.75-fold, to reach 63% at 1 year. 1, 2 One of the most common infections is spontaneous bacterial peritonitis (SBP), with a prevalence ranging from 10% to 30% in hospitalized cirrhotic patients. [3] [4] [5] SBP is mainly caused by bacterial translocation, leading to systemic inflammation, which is a result of the recognition by the immune system of bacterial byproducts coming from the gut. 6, 7 In acute cases, systemic inflammation contributes to the development of multi-organ failure and death. 8 Consequently, the diagnosis must be obtained promptly, as delaying the appropriate treatment causes a fatal outcome in approximately 20-40% of cases. 9 Currently, the gold standard for the diagnosis of SBP is based on a polymorphonuclear (PMN) leukocyte count of ≥250 cells/mm (AF) culture. 10, 11 However, manual microscopic PMN counting in AF is a laborious and time-consuming procedure that also requires a minimum level of expertise to limit intra-and inter-observer variability. Consequently, a manual count sometimes cannot be carried out in general hospitals, especially outside office hours. This drawback could delay the initiation of antibiotic therapy, whereas systematic use of broad-spectrum antibiotics leads to an unjustified risk of iatrogenicity and increased medical costs. Therefore, there is clearly a need for a simple and rapid bedside diagnostic test for SBP. Exciting clinical research has assessed several biomarkers and diagnostic methods to overcome the limitations of the manual cell count, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and among those, the dosage of calprotectin in AF has recently yielded promising results using two methods, namely an enzyme-linked immunosorbent assay (ELISA) [19] [20] [21] or point-of-care testing (POCT). 19, 22 Calprotectin is a calcium-and zinc-binding protein detected mainly in cytosol of neutrophils, and is correlated to the influx of neutrophils in body fluids. 23, 24 Calprotectin is released after neutrophil death or disruption at sites of infection, 25 and shows antimicrobial effects on bacteria as a result of its ability to scavenge manganese and zinc. 26 The amount of calprotectin in feces has become increasingly widespread in the diagnosis and management of inflammatory bowel disease, and also to differentiate between irritable bowel syndrome and inflammatory bowel disease. This evaluation is usually carried out by an ELISA assay, which is time-consuming and also requires a high level of expertise to perform it properly. 27 POCT using the Quantum Blue Reader (BÜHLMANN laboratories AG, Schönenbuch, Switzerland) was recently introduced for the rapid dosage of calprotectin, and a good correlation was found between calprotectin levels obtained by ELISA and using POCT. 19, 28 However, the heterogeneous population included in the study by Burri et al. 19 and the small sample size analyzed in the study by Fernandes et al. 22 preclude any robust conclusions regarding the performance of calprotectin to diagnose SBP.
In the present study, involving a homogeneous cohort of cirrhotic patients with ascites, we aimed to determine the accuracy of calprotectin using the Quantum Blue assay for diagnosing SBP, the level of calprotectin in non-SBP and SBP populations, and the relationship between calprotectin and other biological markers.
METHODS
Study design
T HIS STUDY RECEIVED the approval of our local ethics committee (CPP Est-II) on 18 May 2015 (ref:
15/01), and was carried out in accordance with the Declaration of Helsinki. This non-interventional study involved no additional diagnostic or monitoring procedures for the patients, and blood samples were performed as in normal clinical practice. Oral non-opposition was obtained from all patients included, and all participants received an information document briefly describing the present study. BÜHLMANN laboratories provided the Quantum Blue Reader, but did not participate in any part of the study, including data analysis or manuscript preparation.
Patient characteristics
This study was carried out in two French hospitals (Besançon and Reims) between May 2016 and May 2017, and patients were prospectively and consecutively enrolled. The inclusion criteria were as follows: (i) age ≥18 years; and (ii) ascites due to cirrhosis, based on histological findings or on clinical, biochemical, and/or ultrasonographic findings. Exclusion criteria were the following: (i) chylous or cloudy and macroscopically bloody AF; (ii) patients receiving an antibiotic for >12 h; however, patients under antibiotic prophylaxis and with a clinical suspicion of SBP could be included; and (iii) patients with ascites not related to portal hypertension (e.g. peritoneal carcinomatosis).
Definitions
Paracentesis was carried out on admission or at any time during the hospitalization in aseptic conditions for leukocyte and PMN counts, total protein, and bacteriological status. Total and differential cell counts were performed with an optical microscope. In patients with a red blood cell count >10 000/μL in AF, one PMN was subtracted per 250 red blood cells. Culture of AF was systematically carried out at the bedside by inoculation of 10 mL of AF in both aerobic and anaerobic blood culture bottles. Diagnosis of SBP was based on an absolute PMN count of ≥250/μL in AF.
11 Severity of liver disease was assessed using the Child-Pugh score and the Model for End-Stage Liver Disease (MELD). Criteria for classifying patients as "symptomatic" are reported in Figure S1 . 12 In the first part of this study, calprotectin dosages were carried out to explore: (i) the inter-observer agreement on the day of paracentesis between a biologist (T. J.) and a clinician (D. W.) who was previously trained in the technique; and (ii) the intra-observer (T. J.) agreement on two AF samples originating from the same paracentesis, but analyzed 3 days apart (AF analyzed at day 3 was kept frozen at À20°C). Concentrations of calprotectin were also compared according to the two possible transport modalities at Besançon University Hospital, namely, the pneumatic tube system, and samples hand-carried to the biochemistry laboratory. The Quantum Blue Reader covered a measurable range of calprotectin from 0.18 to 1.80 μg/mL; for the analyses, we approximated the values of calprotectin (values <0.18 μg/mL were registered as 0.17 μg/mL, and those >1.80 μg/mL as 1.81 μg/mL) and we carried out additional rigorous analyses without any approximation.
Dosage of calprotectin
In order to avoid any assessment bias throughout the study, all measurements of calprotectin concentration were carried out before obtaining the results of the reference method (PMN count in AF). Similarly, PMN count was interpreted without knowledge of the calprotectin concentration.
Statistical analysis
Quantitative variables are presented as mean ± standard deviation or median and interquartile range (IQR), and categorical variables as number (percentage). Continuous variables were compared using the Student's t-test or Mann-Whitney test, and categorical variables using the χ 2 -test or Fisher's exact test, as appropriate. Comparison of levels of calprotectin according to the method of transport was carried out using the Wilcoxon matched-pairs signed-rank test. Spearman's rank correlation coefficient was used to explore correlations between calprotectin and other variables. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of calprotectin for the diagnosis of SBP were calculated according to different percentiles of calprotectin values. A first 85th percentile was used, as all upper approximated values (AV; >1.80 μg/mL) were above the calprotectin threshold (1.74 μg/mL) corresponding to this percentile; calculation was thereafter carried out every 5 percentiles up to the 55th percentile. For each indicator, 95% confidence intervals (95% CI) were calculated from exact confidence limits based on the binomial distribution. Statistical analyses were carried out using NCSS for Windows (2010) and SAS version 9.4 (SAS Institute, Cary, NC, USA). A P-value <0.05 was considered statistically significant.
RESULTS
Study population
A TOTAL OF 273 paracenteses were carried out on 128 patients, of whom 22 paracenteses (14 patients) were included in Reims Hospital. This center entered the present study late, explaining the low number of patients included.
The main characteristics of the study population with calprotectin available in AF (119 patients) are shown in Table 1 . The mean age of patients was 62.0 ± 11.4 years, 84% were men. The leading etiology of cirrhosis was alcohol in 70%. The main reason for admission was ascites requiring paracentesis (79% of cases). Hepatocellular , and the isolated bacteria were as follows: Streptococcus (n = 2), Staphylococcus (n = 2), Enterococcus (n = 3), Escherichia coli (n = 7), Klebsiella (n = 4), and Morganella morganii (n = 1). Among the 236 AF samples, 100 (42.4%) were from patients receiving antibiotics, either for primary or secondary prophylaxis of SBP (25 were receiving norfloxacin) or for prophylaxis of hepatic encephalopathy (two receiving rifaximin), or for suspected or documented bacterial infection (n = 73). Table 2 describes the clinical characteristics at the time of paracenteses, according to whether AF was considered as SBP or not. Nearly 56% of AF samples were taken from "symptomatic" patients, but just 18% of "symptomatic" patients had SBP. Among patients with SBP, 61% were "symptomatic," mainly due to abdominal tenderness. The PMN count in SBP ranged from 285/μL to 12 750/μL, whereas the PMN count was <1000/μL and 500/μL in 16 (44.4%) and 8 (22.2%) SBP, respectively. At the time of SBP diagnosis, cirrhotic patients with SBP had more severe liver function (median MELD score: 22 vs. 16; P = 0.006) and a more pronounced increase in median blood leukocyte count (8700 vs. 7080 mm À3 ; P = 0.039) than patients without SBP, but the median total protein concentration in AF was similar between patients with and without SBP ( Table 2) .
Relationship between calprotectin and other variables
During the preliminary analytical phase, we did not observe any significant difference in median concentrations of calprotectin (as assessed for measurable values of calprotectin only) between samples transported in a pneumatic tube system (0.36 μg/mL, IQR 0.19-0.67 μg/mL) versus hand-carried samples (0.34 μg/mL, IQR 0.20-0.69 μg/mL; P = 0.64). We decided to hand-carry all AF samples. Second, inter-and intra-observer agreement, evaluated in 26 AF samples, showed very good agreement with intra-class correlation coefficients of 0.95 and 0.89, respectively (File S1 and Figs S2,S3 in the supplementary appendix).
Calprotectin levels with and without AV were positively correlated with PMN in AF (r = 0.57, P < 0.001 and r = 0.33, P < 0.001), C-reactive protein (CRP; r = 0.43, P < 0.001 and r = 0.19, P = 0.036), and total protein concentration in AF (r = 0.42, P < 0.001 and r = 0.34, P < 0.001). Calprotectin levels using AV were not influenced by the etiology of liver cirrhosis (alcohol vs. other causes; P = 0.41), sex (P = 0.10), age (P = 0.84), or ChildPugh (P = 0.86) or MELD scores (P = 0.49). Among the 36 SBP samples with available calprotectin, calprotectin levels using AV did not vary significantly, regardless of whether AF culture was positive or not (P = 0.10).
Diagnostic performance of calprotectin
Patients with SBP had significantly higher median levels of calprotectin (1.81 μg/mL) than patients without SBP (0.25 μg/mL; P < 0.001; Fig. 2 ). Using percentiles of calprotectin values, the best threshold value optimizing the Youden Index (sensitivity + specificity-1) to diagnose SBP was 1.51 μg/mL (Table 3) . Among 236 AF samples with available calprotectin dosage, there were five false negative (2.1%), 16 false positive (6.8%), 184 true negative (78.0%), and 31 true positive (13.1%) cases at a threshold of 1.51 μg/mL; that is, 91.1% correctly classified The median calprotectin level of the five false negative cases was 0.45 μg/mL (range 0.24-0.76), and none of these patients received antibiotic prophylaxis at the time of paracentesis. Biological data (Child-Pugh, MELD score, natremia, bilirubin, and creatinine levels) and clinical data (symptoms suggestive of SBP) did not make it possible to discriminate false negative and true positive cases, but the number of false negative cases was too small for robust statistical analysis. False negative cases showed a trend towards lower serum leukocyte count, natremia, albumin, and higher bilirubin levels and Child-Pugh score, as compared with true positive cases (Table 4) . Only one asymptomatic 70-year-old alcoholic cirrhotic man had SBP with a low calprotectin level at 0.45 μg/mL; the severity of liver cirrhosis was classified as Child-Pugh C, CRP was 78 mg/L, and PMN count in AF was 392/μL. Overall, the five false negative cases had higher median CRP levels than the 184 true negative cases (62.4 mg/L [IQR 30.4- Figure S1 .
DISCUSSION
S
BP IS A dreaded complication of portal hypertension, and might be asymptomatic or associated with non-specific clinical symptoms. 29 As a consequence, prompt diagnostic paracentesis should be carried out in all patients with cirrhosis and ascites at hospital admission, and whenever patients develop complications, such as bleeding, hepatic encephalopathy, and renal failure, in order to rule out SBP. 30 The diagnosis of SBP is currently based on neutrophil count in AF, using a manual cell count, although this procedure can sometimes be challenging, because it is time-consuming and requires sufficiently experienced personnel. Alternative approaches have been attempted, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] but so far, none has been endorsed by leading scientific societies in hepatology. 10, 11 We present here the results of the largest study to date to assess calprotectin for the prompt diagnosis of SBP in a homogeneous cohort of hospitalized cirrhotic patients with ascites. The prevalence of SBP in the present cohort (15.2%) is in agreement with that usually found in inpatients (8-36% 31 ). We observed that calprotectin measurement in AF samples was a simple procedure that did not require skilled laboratory personnel, and it can be routinely carried out at the bedside or in proximity to the patient's bedroom in <15 min using POCT. Our preliminary analyses confirmed good inter-and intra-observer reproducibility for the measurement of calprotectin using the Quantum Blue assay, and we first showed that the pneumatic tube system did not affect the values of calprotectin in AF, as compared with hand-carrying the samples to the laboratory. More interestingly, this test was able to confidently exclude SBP (NPV 97.3%) using a threshold of 1.51 μg/mL.
We did not measure calprotectin levels in AF using the standard ELISA technique, because the main aim of the present study was to implement a rapid and useful technique for clinicians to diagnose SBP, and also because the ELISA technique requires trained personnel to adequately carry out the elaborate steps involved. 19 Furthermore, Burri et al. observed an excellent correlation (r = 0.873, P < 0.001), and a good degree of agreement between the two tests in their entire heterogeneous cohort; 19 considering the subgroup of cirrhotic patients, the ELISA and POCT yielded similar diagnostic capability for identifying PMN >250/μL (AUC for ELISA and POCT of 0.987 and 0.982, respectively). In the present study, POCT was falsely negative in only one asymptomatic patient (calprotectin level was 0.45 μg/mL), but this patient had a high level of serum CRP (78 mg/L), which was a strong signal in favor of SBP. The four other false negative cases were all "symptomatic" and required standard cytology to definitively exclude SBP. It is noteworthy to observe that the median level of CRP (62.4 mg/L, range 20-89 mg/L) in false negative cases did not differ significantly from the true positive cases (72.5 mg/L; Table 4 ), but was higher than that associated with true negative (23.7 mg/L; P = 0.019) or false positive (37 mg/L; P = 0.24) cases. This observation must prompt us to suspect SBP whenever POCT is negative but associated with a high level of CRP. This protein of the acute phase of inflammation remains elevated even in the context of advanced liver failure, and its value reflects the degree of systemic inflammation, regardless of its cause. 32 We also recently showed the strong prognostic value of CRP in different cohorts of cirrhotic patients, 33, 34 but the capacity of CRP to diagnose SBP was less relevant than calprotectin measurement in AF in the present study (AUC 0.83 vs. AUC 0.90 for calprotectin; P = 0.18; Fig. S4 ).
To the best of our knowledge, just four studies have evaluated the dosage of calprotectin in AF to diagnose SBP, [19] [20] [21] [22] and just two of them reported data on the most interesting method; that is, POCT. 19, 22 In the prospective Swiss study, calprotectin levels in AF were measured in 130 AF samples from 71 patients, and 19 AF were considered as SBP (PMN count >250/μL). 19 Using an optimal threshold of 0.51 μg/mL, the diagnostic performance of calprotectin using POCT was remarkable (sensitivity 100% and NPV 100%), but these results were mitigated by the heterogeneous population analyzed (11 patients had malignant ascites), and just four SBP were in patients with liver cirrhosis. More recently, Fernandes et al. measured calprotectin in 88 AF samples (41 SBP and 47 non-SBP) in a homogeneous cohort of patients with liver cirrhosis (median MELD score 18, alcohol 79%) similar to the present study's cirrhotic population. 22 Using an optimal threshold of 1.57 μg/mL, POCT had a fairly good capacity to diagnose or exclude SBP (sensitivity 87.8%, specificity 97.9%, PPV 97.3%, and NPV 90.2%). Our lower PPV (65.9%), as compared with the 97.3% observed previously, 22 might be explained by the lower threshold used in the present study (1.51 μg/mL), which inevitably increases the number of true positive, but also of false positive cases, thus contributing to the decrease in PPV. For clinical decision-making in life-threatening disease (such as SBP), the NPV (97.3% in the present study) must be preferred. Although the study by Fernandes et al. appears well designed, the sample size (n = 88) was quite low, and the upper limit of the range of calprotectin was 18 μg/mL, which differs from the present study (1.80 μg/mL). 22 This larger range of calprotectin values is surely more appropriate to investigate its performance, but such an extension implies carrying out additional dilution of AF (1:50 with chase buffer for dosages >1.80 μg/mL according to the manufacturer's instructions), which has not been well evaluated. Furthermore, the diluted AF samples must be tested again with a new cassette, and the concentration thus measured must be multiplied by the volume factor ×10 to obtain the final result. Due to the lack of robust data regarding the dispersion of calprotectin between 1.80 and 18 μg/mL, and also due to the additional cost incurred by using a second cassette to obtain the final dosage, we decided to measure calprotectin within the range proposed by the manufacturer (from 0.18 to 1.80 μg/mL), and to approximate all values exceeding these limits to 0.17-1.81 μg/mL. To circumvent such approximations and to yield more accurate results regarding the performance of calprotectin in AF to diagnose or exclude SBP, we used different percentiles of calprotectin values. The estimated costs for dosage of calprotectin in AF (dosage not covered by the French social security system), and for a standard manual cell count are respectively 16€ and 27€, but the cost of calprotectin dosage could increase to 47€ if a second cassette is used to obtain a dosage >1.80 μg/mL. We acknowledge that the present study suffers from the following limitations. First, the range of calprotectin values recommended by the manufacturer (i.e. 0.18-1.80 μg/mL) is inadequate to consider the highest values (in the present study, 44 calprotectin values (18.6%) were >1.80 μg/mL), and the dispersion of high values was not investigated in depth; similarly, 71 calprotectin values were <0.18 μg/mL and were rounded to 0.17 for a more comprehensible analytical approach. Second, overall, 37 calprotectin dosages (13.5%) could not be analyzed, mainly due to chylous/cloudy or bloody conditions (8.4%). Previous studies did not provide data regarding the performance of the Quantum Blue assay in ascites contaminated with erythrocytes or hemoglobin or in chylous/cloudy ascites; 19, 22 this information should have been clearly reported, as any blood supply containing neutrophils might release calprotectin in AF and, consequently, could overestimate the true value of calprotectin. Thus, to ensure homogeneous results, we excluded these samples, as in a previous report. 13 Bloody and cloudy/chylous ascites were infrequent in the present study (4.9% and 3.3%, respectively), and the diagnostic performance of the Quantum Blue assay in such conditions remains unclear. Third, the present cohort constituted hospitalized patients, and none were treated in an ambulatory setting. As the present data cannot be generalized to outpatients, the evaluation of calprotectin in AF should be further investigated in this population, who are likely to yield a benefit from rapid screening. Indeed, outpatients have a short hospital stay, meaning that the results of AF cytology are not always available before hospital discharge, and consequently, alternative approaches for the diagnosis of SBP in this setting are of particular interest. To carry out such a study, a large sample of outpatients with ascites would be required to determine the diagnostic performance of calprotectin in AF for SBP, as this population has a low risk of SBP (≤3.5%). 35 Despite these drawbacks, the very similar optimal threshold of calprotectin found in the present study (1.51 μg/mL) and that by Fernandes et al.
(1.57 μg/mL) strengthens the robustness of the present data and the interest of measuring calprotectin in AF to diagnose and, above all, to exclude SBP in hospitalized patients.
In conclusion, the dosage of calprotectin in AF using the Quantum Blue Reader POCT is a rapid method that can be carried out by untrained operators. This test is an attractive approach for clinicians to exclude SBP in hospitalized cirrhotic patients thanks to its excellent NPV (97.3%), without the need to carry out standard ascitic cytology, providing the patient is asymptomatic or has a nearnormal CRP level, suggesting the absence of an ongoing inflammatory state. Using this test for emergency diagnosis of SBP might also be useful, wherever the patient is, to enable timely administration of antibiotics, especially during off-hours, when cytology is not always feasible. Further analytical studies are required to assess in greater depth the dispersion of calprotectin values in the lower and, above all, upper limits of the range reported by the manufacturer. We also need to improve our understanding of why some cases of SBP associated with an inflammatory process, as reflected here by CRP levels >20 mg/L, had low levels of calprotectin. Figure S4 Receiver operating characteristic curve of calprotectin levels for the prediction of spontaneous bacterial peritonitis File S1 Results: preliminary analyses.
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